Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
affecting upper and lower motor neurons, with death resulting mainly from respiratory failure …

Background Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative
disease, and the time from symptom onset to diagnosis remains long. With the advent of …

The care and management of patients with ALS should always be patient focused, with
attention to holistic and emotional aspects of well-being. It is the patient who ultimately …

Objective To determine the prevalence and prognostic value of weight loss (WL) prior to
diagnosis in patients with amyotrophic lateral sclerosis (ALS). Methods We enrolled patients …

Objective: Weight loss in amyotrophic lateral sclerosis (ALS) is associated with faster
disease progression and shorter survival. It has different possible causes, including loss of …

Objective To unveil clinical features, comorbidities, disease progression and prognostic
factors in a population-based cohort of ALS patients carrying C9ORF72 expansion (C9+ …

Background Body weight reduction after disease onset is an independent predictor of
survival in amyotrophic lateral sclerosis (ALS), but significance of weight variation after …

Increased incidence rates of amyotrophic lateral sclerosis (ALS) have been recently
reported across various Western countries, although geographic and temporal variations in …

Amyotrophic lateral sclerosis (ALS) causes dysphagia and consequent poor nutrition.
Sometimes enteral feeding is offered. Percutaneous endoscopic gastrostomy (PEG) is …

Background Oral tauroursodeoxycholic acid (TUDCA) is a commercial drug currently tested
in patients with amyotrophic lateral sclerosis (ALS) both singly and combined with sodium …